A Phase 3, Randomized, Double-Blind, Placebo-Controlled Trial of Flecainide Acetate Inhalation Solution for Cardioversion of Recent-Onset, Symptomatic Atrial Fibrillation to Sinus Rhythm
Latest Information Update: 08 Oct 2024
At a glance
- Drugs Flecainide (Primary)
- Indications Paroxysmal atrial fibrillation
- Focus Registrational; Therapeutic Use
- Acronyms RESTORE-1
- Sponsors InCarda Therapeutics
- 30 Sep 2024 Results published in the InCarda Therapeutics Media Release
- 02 Sep 2024 According to a InCarda Therapeutics media release, data from this trial were presented at the 2024 European Society of Cardiology meeting
- 07 Jun 2023 Status changed from recruiting to discontinued.